Chronic Hand Eczema

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

High-dose topical delgocitinib significantly outperformed oral alitretinoin in reducing HECSI severity at both 12 and 16 weeks.

Clinical trials DELTA 1, 2, 3, and DELTA FORCE demonstrated significant improvements in CHE severity and patient-reported outcomes with delgocitinib.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

New research highlights the link between isotretinoin dosage and increased chronic hand eczema, emphasizing the need for careful monitoring during acne treatment.

Delgocitinib showed consistent efficacy in atopic, irritant, allergic, and hyperkeratotic forms of chronic hand eczema in pooled trial data.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Late-breaking EADV 2025 presentations highlighted positive efficacy outcomes in the adolescent population and pooled safety data across 5 phase 2b and phase 3 trials of delgocitinib cream.

LEO Pharma's delgocitinib cream for chronic hand eczema is now available to prescribe in the US.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Most physicians continue to prescribe topical corticosteroids despite prior treatment failure.

Test your knowledge of key words and terms associated with the recent approval of delgocitinib for adults with moderate to severe CHE.

Explore the complexities of chronic hand eczema, its impact on quality of life, and emerging treatment options in this insightful review.

The drug’s approval in August 2025 follows robust efficacy and safety results from the DELTA 1, 2, and 3 clinical trials.

Delgocitinib cream recently became the first FDA-approved treatment for chronic hand eczema. Robert Spurr of LEO Pharma shares insights into what it means for providers and patients.

The approval makes delgocitinib cream the first and only approved therapy in the US for CHE in adults.

A national Delphi survey reveals critical insights into CHE management in France, highlighting the need for standardized assessment and guidelines.

Delgocitinib cream offers a safe, effective treatment for chronic hand eczema with minimal systemic absorption, ensuring no significant immunosuppressive effects.

Click here to answer our poll.

LEO Pharma reveals promising interim results for tralokinumab in treating moderate to severe atopic dermatitis on hands, enhancing patient quality of life.

Explore innovative strategies for managing chronic hand eczema, focusing on personalized care, early treatment, and understanding complex subtypes for better outcomes.

A study reveals the significant emotional burden of work-related chronic hand eczema, highlighting the need for tailored psychological support for affected patients.

Global studies from LEO Pharma highlight the diagnostic gaps, quality-of-life burdens, and treatment landscape for patients with CHE.

At the Fall Clinical PA/NP 2025 Conference, attendees caught up on the ins and outs of CHE.

Jonathan Silverberg, MD, PhD, MPH, shares his insights on treating and managing CHE.